CELL INTELLIGENCE · 肿瘤细胞治疗研究

靶向白血病干细胞的脂质体纳米免疫疗法通过沉默 B 细胞淋巴瘤 2 逆转免疫逃逸并抑制融合癌蛋白驱动的急性髓系白血病

Leukemic Stem Cell-Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein-Driven Acute Myeloid Leukemia by Silen

多功能 CD38 在 B 细胞淋巴瘤发病机制和治疗中的作用

Multifunctional CD38 in the pathogenesis and treatment of B-cell lymphomas.

多发性骨髓瘤与拟态：CAR-T 细胞治疗和抗 CD38 单克隆抗体治疗后患者的胃肠道组织学表现

Multiple Myeloma and Mimicry: Gastrointestinal Tract Histologic Findings in Patients Following Chimeric Antigen Receptor T-cell Therapy and Anti-CD38

靶向 CD19 CAR-T 细胞治疗的非 ICANS 神经毒性与运动及神经认知治疗中出现的不良事件：一例病例报告

Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case

双特异性抗体在多发性骨髓瘤中的演进

The evolution of bispecific antibodies in multiple myeloma.

单采 CD8(+)CCR7(+)CD45RA(-) T 细胞作为与 CAR-T 细胞动力学和临床结局相关的新型生物标志物

Apheresis CD8(+)CCR7(+)CD45RA(-) T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome.

达雷妥尤单抗治疗 CD20(-)CD38(+) 复发/难治性弥漫大 B 细胞淋巴瘤

Daratumumab for CD20(-)CD38(+) Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

CAR-T 细胞治疗急性髓系白血病：目前所处的位置

CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?

BNT162b2 mRNA 疫苗接种影响滤泡性淋巴瘤和慢性淋巴细胞白血病患者的肠道微生物组组成

BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia.

达雷妥尤单抗和维奈克拉序贯 CAR-T 细胞治疗难治性 p53 突变大 B 细胞淋巴瘤：病例报告和动物研究

Treatment of Refractory p53 Mutation Large B-cell Lymphoma with Daratumumab and Venetoclax Followed by CAR-T Cell Therapy: Case Report and Animal Stud

我们成功的病例和动物实验结果，为伴有 p53 突变的复发/难治性大 B 细胞淋巴瘤的治疗提供了新途径。需要进一步开展临床试验，以 daratumumab 联合 venetoclax 治疗 CD38 阳性淋巴瘤。